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Decision curve analysis has become increasingly common, as noted by Capogrosso and Vickers. 1 This is welcome news to the decision-analysis community, as decision-analytic methods include more relevant information than purely statistical methods. The challenge with using standard decision-analytic methods to evaluate risk prediction has been specifying benefits and costs. Decision curve analysis circumvents this difficulty by using a sensitivity analysis based on a range of risk thresholds. 2 A risk threshold is the probability of the event of interest (usually the occurrence of disease) at which one is indifferent between no treatment and treatment. 3 Capogrosso and Vickers 1 listed criteria for the good practice of decision curve analysis and found that most of the studies they examined satisfied their criteriaagain more good news. However, readers of Capogrosso and Vickers may come away with a mistaken view that decision curves are the only decision-analytic methods involving risk thresholds. A useful alternative to decision curves is relative utility curves, which uses the risk in the target population for the risk threshold and has a rigorous theoretical basis. [4] [5] [6] [7] Relative utility curves and decision curves have different theoretical underpinnings. A brief review of these differences adds perspective to the criteria for good practice for decision curve analysis discussed by Capogrosso and Vickers.
Relative utility is the maximum net benefit of risk prediction (excluding the cost of data collection) at a given risk threshold divided by the maximum net benefit of perfect prediction. It ranges from 0 (chance prediction) to 1 (perfect prediction). With relative utility curves, net benefit is the total expected benefits minus the total expected costs, the standard definition in benefit-cost analysis. 8 With decision curves, net benefit is the standard net benefit divided by the benefit of a true-positive prediction. 2 A decision curve analysis plots net benefit versus risk threshold for prediction versus treat-none and treat-all versus treat-none, each with a separate curve. A relative utility curve plots relative utility versus risk threshold for prediction versus treat-all, on the left side where treat-all is preferred to treat-none, and prediction versus treat-none on the right side, where treat-none is preferred to treat-all.
A relative utility curve analysis begins with a risk prediction model obtained from training data. The goal is to evaluate the risk prediction model in an independent test sample, which is ideally a random sample from a target population, possibility stratified by event and no event. Unlike a decision curve analysis, a relative utility analysis requires a concave receiver-operating characteristic (ROC) curve (or the concave envelope of an ROC curve). A relative utility curve plots relative utility as a function of the probability of the event in the target population and the test's true-positive and false-positive rates versus a risk threshold.
Importantly, the risk threshold in a relative utility curve corresponds to the risk in the target population. In contrast, in decision curves, the risk threshold corresponds to the predicted risk in the training sample. Consequently, calibration, adjusting the risk from the training sample to match the risk in the test sample (and ideally to match the risk in the target population), is important for proper application of decision curves-a criterion not listed in Capogrosso and Vickers. Poor calibration can yield very misleading decision curves, [9] [10] [11] particularly when the training sample is artificially created by separate sampling of cases and controls.
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with decision curves, yielding a meaningful decisionanalytic statement about the cost or harm of data collection without explicitly specifying these costs or harms. The test tradeoff is the minimum number of persons receiving a test that would be traded for a true positive so that the net benefit of risk prediction is positive. Investigators need only decide if the test tradeoff is acceptable given the type of data collection. For example, a test tradeoff of data collection in 3000 persons for every true prediction of breast cancer risk may be acceptable if data collection involves a questionnaire or an inexpensive genetic test but likely unacceptable if it involves an invasive test. Capogrosso and Vickers do not mention test tradeoffs, but they are starting to be used with decision curves. 12 In summary, Capogrosso and Vickers have made a valuable contribution by recognizing the growing use of decision curve analyses satisfying their criteria for good practice. However, the criteria should be expanded to include calibration of the predicted risk from the training sample to the risk in the test sample and ideally the target population, so that the risk threshold is on the appropriate scale. In addition, when using either decision curves or relative utility curves, it is worthwhile to report the test tradeoff when there are nonnegligible data collection costs.
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